London: July 21, 2020. University of Oxford para bona COVID-19 vaccine experiment kurikena safe ase aro healthy volunteers khan logot clinical trials samay early-stage te immune response tuh pai koikena Monday din data para thikaishe. Etu vaccine nam tuh AZD1222 ase aro pharmaceutical company AstraZeneca aro Britain’s University of Oxford laga scientist khan para bonaishe. Lancet medical journal te khobor deya hesab te, vaccine laga trail result para eku serious side effects nahoi aro elicited antibody aro T-cell immune responses tuh bhal ase koishe.
“ami khan besas ase ke, immune system para virus ke yaat thaki-kena ami khan laga vaccine para manuh khan ke besi deri samay pachai-kena rabo, koikena University of Oxford laga lead author Andrew Pollard para janai thishe. Hoilebi, vaccine para SARS-CoV-2 (COVID-19) bemar ke bhal para protect koriase confirm nakora ake te, ami khan aro beshi research kuriboli lage” author Andrew Pollard para aro koishe. Etai dak te bema roper te AstraZeneca tuh leading vaccine candidate ase, etu bemari para 600,000 oper manuh laga jaan jaikena ase koishe.
Vaccines bona pithor te, China khan para be Sinovac Biotech bonaiase aro dosura ekta state-owned Chinese firm Sinopharm para be bonai ase aro ekta tuh U.S. laga biotech firm Moderna para be bonai ase koishe. AstraZeneca tuh Duniyaa sob logot agreement signed kurikena tai khan laga vaccine tuh supply thiboli ase, etu nemite vaccine para bhal kam thiboli lage aro approval hobole koishe. Etu samay Company para koishe ke, etai bemari thaka samay tai khan vaccine oper te profit nemite kam nakoriboli koishe. Researchers khan para aro janai thishe te, etu vaccine para side effects olop tuh dey, hoilebi paracetamol tawai loile bhal hoi aro vaccine paa dosura eku serious natey koishe.
Add Comment